|
1
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aghajanian C, Blank SV, Goff BA, Judson
PL, Teneriello MG, Husain A, Sovak MA, Yi J and Nycum LR: OCEANS: A
randomized, double-blind, placebo-controlled phase III trial of
chemotherapy with or without bevacizumab in patients with
platinum-sensitive recurrent epithelial ovarian, primary
peritoneal, or fallopian tube cancer. J Clin Oncol. 30:2039–2045.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Naora H and Montell DJ: Ovarian cancer
metastasis: Integrating insights from disparate model organisms.
Nat Rev Cancer. 5:355–366. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brodsky AS, Fischer A, Miller DH, Vang S,
MacLaughlan S, Wu HT, Yu J, Steinhoff M, Collins C, Smith PJ, et
al: Expression profiling of primary and metastatic ovarian tumors
reveals differences indicative of aggressive disease. PLoS One.
9:e944762014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lengyel E: Ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Scotton CJ, Wilson JL, Scott K, Stamp G,
Wilbanks GD, Fricker S, Bridger G and Balkwill FR: Multiple actions
of the chemokine CXCL12 on epithelial tumor cells in human ovarian
cancer. Cancer Res. 62:5930–5938. 2002.PubMed/NCBI
|
|
7
|
Houle CD, Ding XY, Foley JF, Afshari CA,
Barrett JC and Davis BJ: Loss of expression and altered
localization of KAI1 and CD9 protein are associated with epithelial
ovarian cancer progression. Gynecol Oncol. 86:69–78. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Deng J, Wang L, Chen H, Li L, Ma Y, Ni J
and Li Y: The role of tumour-associated MUC1 in epithelial ovarian
cancer metastasis and progression. Cancer Metastasis Rev.
32:535–551. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang L, Volinia S, Bonome T, Calin GA,
Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K,
et al: Genomic and epigenetic alterations deregulate microRNA
expression in human epithelial ovarian cancer. Proc Natl Acad Sci
USA. 105:7004–7009. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rich JN, Hans C, Jones B, Iversen ES,
McLendon RE, Rasheed BK, Dobra A, Dressman HK, Bigner DD, Nevins JR
and West M: Gene expression profiling and genetic markers in
glioblastoma survival. Cancer Res. 65:4051–4058. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bindea G, Mlecnik B, Hackl H, Charoentong
P, Tosolini M, Kirilovsky A, Fridman WH, Pagès F, Trajanoski Z and
Galon J: ClueGO: A Cytoscape plug-in to decipher functionally
grouped gene ontology and pathway annotation networks.
Bioinformatics. 25:1091–1093. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Luo W and Brouwer C: Pathview: An
R/Bioconductor package for pathway-based data integration and
visualization. Bioinformatics. 29:1830–1831. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Szklarczyk D, Franceschini A, Kuhn M,
Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork
P, et al: The STRING database in 2011: Functional interaction
networks of proteins, globally integrated and scored. Nucleic Acids
Res. 39:(Database issue). D561–D568. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ru Y, Kechris KJ, Tabakoff B, Hoffman P,
Radcliffe RA, Bowler R, Mahaffey S, Rossi S, Calin GA, Bemis L and
Theodorescu D: The multiMiR R package and database: Integration of
microRNA-target interactions along with their disease and drug
associations. Nucleic Acids Res. 42:e1332014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qian F, Engst S, Yamaguchi K, Yu P, Won
KA, Mock L, Lou T, Tan J, Li C, Tam D, et al: Inhibition of tumor
cell growth, invasion, and metastasis by EXEL-2880 (XL880,
GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine
kinases. Cancer Res. 69:8009–8016. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shi MD, Liao YC, Shih YW and Tsai LY:
Nobiletin attenuates metastasis via both ERK and PI3K/Akt pathways
in HGF-treated liver cancer HepG2 cells. Phytomedicine. 20:743–752.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ye M, Hu D, Tu L, Zhou X, Lu F, Wen B, Wu
W, Lin Y, Zhou Z and Qu J: Involvement of PI3K/Akt signaling
pathway in hepatocyte growth factor-induced migration of uveal
melanoma cells. Invest Ophthalmol Vis Sci. 49:497–504. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chan KHB: Effect of CAL-101 on gene
regulation of phosphoinositol 3-kinase isoform p110δ in the
pathogenesis of glioblastoma multiforme. 2013.
|
|
19
|
Uyama N, Iimuro Y, Kawada N, Reynaert H,
Suzumura K, Hirano T, Kuroda N and Fujimoto J: Fascin, a novel
marker of human hepatic stellate cells, may regulate their
proliferation, migration, and collagen gene expression through the
FAK-PI3K-Akt pathway. Lab Invest. 92:57–71. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Moriya C, Jinnin M, Yamane K, Maruo K,
Muchemwa FC, Igata T, Makino T, Fukushima S and Ihn H: Expression
of matrix metalloproteinase-13 is controlled by IL-13 via PI3K/Akt3
and PKC-δ in normal human dermal fibroblasts. J Invest Dermatol.
131:655–661. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wolf K and Friedl P: Mapping proteolytic
cancer cell-extracellular matrix interfaces. Clin Exp Metastasis.
26:289–298. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu YH, Chang TH, Huang YF, Huang HD and
Chou CY: COL11A1 promotes tumor progression and predicts poor
clinical outcome in ovarian cancer. Oncogene. 33:3432–3440. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kumar S, Kumar A, Shah PP, Rai SN,
Panguluri SK and Kakar SS: MicroRNA signature of cis-platin
resistant vs. cis-platin sensitive ovarian cancer cell lines. J
Ovarian Res. 4:172011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cui J, Miner BM, Eldredge JB, Warrenfeltz
SW, Dam P, Xu Y and Puett D: Regulation of gene expression in
ovarian cancer cells by luteinizing hormone receptor expression and
activation. BMC Cancer. 11:2802011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Abbott KL, Lim JM, Wells L, Benigno BB,
McDonald JF and Pierce M: Identification of candidate biomarkers
with cancer-specific glycosylation in the tissue and serum of
endometrioid ovarian cancer patients by glycoproteomic analysis.
Proteomics. 10:470–481. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Park K, Chung YJ, So H, Kim K, Park J, Oh
M, Jo M, Choi K, Lee EJ, Choi YL, et al: AGR2, a mucinous ovarian
cancer marker, promotes cell proliferation and migration. Exp Mol
Med. 43:91–100. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gagné JP, Éthier C, Gagné P, Mercier G,
Bonicalzi ME, Mes-Masson AM, Droit A, Winstall E, Isabelle M and
Poirier GG: Comparative proteome analysis of human epithelial
ovarian cancer. Proteome Sci. 5:162007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ahmed AA, Mills AD, Ibrahim AE, Temple J,
Blenkiron C, Vias M, Massie CE, Iyer NG, McGeoch A, Crawford R, et
al: The extracellular matrix protein TGFBI induces microtubule
stabilization and sensitizes ovarian cancers to paclitaxel. Cancer
Cell. 12:514–527. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cheon DJ, Tong Y, Sim MS, Dering J, Berel
D, Cui X, Lester J, Beach JA, Tighiouart M, Walts AE, et al: A
collagen-remodeling gene signature regulated by TGF-β signaling is
associated with metastasis and poor survival in serous ovarian
cancer. Clin Cancer Res. 20:711–723. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen Q, Xu R, Zeng C, Lu Q, Huang D, Shi
C, Zhang W, Deng L, Yan R, Rao H, et al: Down-regulation of Gli
transcription factor leads to the inhibition of migration and
invasion of ovarian cancer cells via integrin β4-mediated FAK
signaling. PLoS One. 9:e883862014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Han XG, Li Y, Mo HM, Li K, Lin D, Zhao CQ,
Zhao J and Tang TT: TIMP3 regulates osteosarcoma cell migration,
invasion, and chemotherapeutic resistances. Tumor Biol.
37:8857–8867. 2016. View Article : Google Scholar
|
|
32
|
Arpino V, Brock M and Gill SE: The role of
TIMPs in regulation of extracellular matrix proteolysis. Matrix
Biol. 44–46:247–254. 2015. View Article : Google Scholar
|
|
33
|
Stope MB, Delogu S, Diesing K, Klinkmann
G, Evert M, Koensgen D, Zygmunt M, Burchardt M and Mustea A:
Expression pattern of the microRNA miR-1 in ovarian cancer cell
lines and tumor tissue samples implies a loss of miR-1's tumor
suppressor properties. Rna Disease. 1:e3842014.
|
|
34
|
Vacchi-Suzzi C, Hahne F, Scheubel P,
Marcellin M, Dubost V, Westphal M, Boeglen C, Büchmann-Møller S,
Cheung MS, Cordier A, et al: Heart structure-specific
transcriptomic atlas reveals conserved microRNA-mRNA interactions.
PLoS One. 8:e524422013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tsoutsman T, Wang X, Garchow K, Riser B,
Twigg S and Semsarian C: CCN2 plays a key role in extracellular
matrix gene expression in severe hypertrophic cardiomyopathy and
heart failure. J Mol Cell Cardiol. 62:164–178. 2013. View Article : Google Scholar : PubMed/NCBI
|
